Multimedia News Release – New Hope For Stroke Patients: A Medical First Benefits Patient At Illinois Hospital
WINFIELD, Ill., Dec. 6 /PRNewswire/ — A promising new catheter-based device, NeuroFlo, designed to increase blood flow to the brain during a stroke, was recently used on a stroke victim for the first time as part of a Phase 3 clinical trial at Central DuPage Hospital (CDH).
To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/centraldupage/23271/
By the time a 51-year-old mother of three arrived at CDH, a regional stroke center in Chicago’s western suburbs, nearly eight hours had passed since the onset of stroke symptoms, too late for usual FDA-approved therapies. Fortunately she was eligible for a new clinical trial available at the hospital.
The procedure was performed successfully and the patient left the hospital within a week and is recovering at home. Without Central DuPage Hospital’s participation in the trial, she would have had no other treatment options.
The Downers Grove, Ill. resident became the first patient in the U.S. to participate in the national clinical trial of the CoAxia(TM) NeuroFlo(TM) Perfusion Augmentation technology. The device is designed to minimize damage from an acute stroke and extend the time a stroke patient can be treated. As intended, in this case, the NeuroFlo device restored blood flow to the area of the patient’s brain which was at risk for damage due to stroke.
In this study, the NeuroFlo procedure can be used up to 10 hours after stroke symptoms occur. Currently, the most common intervention is a clot- dissolving agent, I.V. tPA (intravenous tissue plasminogen activator) that must be administered within three hours of symptom onset. Less than four percent of stroke patients nationwide receive tPA treatment, and of those who do receive the drug, only one of seven will benefit.
Harish Shownkeen, MD, Director of Endovascular Surgical NeuroRadiology at CDH, along with multiple neurologists, is leading the hospital’s investigation of the new treatment: “This is a significant advancement in the study of emergency stroke treatment and we are all encouraged by how well this patient is doing. In fact, today we are where cardiology was 15 or 20 years ago. We are turning the corner and there is new hope for stroke victims due to a variety of new trials found at several hospitals, including Central DuPage Hospital.”
The NeuroFlo device is a catheter-based device comprised of two balloons. The catheter is inserted at the femoral artery using high-definition intravascular x-ray imaging to guide the tiny device to the renal arteries. From there, the interventional neuroradiologist inflates the NeuroFlo balloons to potentially redirect blood flow to the brain. By restoring blood flow to the brain quickly, it’s possible to prevent further tissue damage and allow cells in the stroke area to recover.
The FDA-controlled study of NeuroFlo will continue for approximately two years.
About CDH
Central DuPage Hospital is a nationally recognized 361-bed facility located in Winfield, Illinois, a suburb of Chicago. In 2005, Central DuPage Hospital was recognized for excellence in stroke specialty by HealthGrades, a leading provider of independent hospital ratings. The Neuroscience Department of CDH is extensive, encompassing treatment for spinal conditions, brain tumors and injury, stroke, movement and memory disorders as well as specialized programs for treatment of sleep disorders and pain. CDH was first in the region to develop a comprehensive program to treat stroke victims in the emergency room with t-PA. CDH has a bi-plane angiography suite with 3D angiogram capabilities specifically designed for interventional neuroradiology procedures.
Video: http://www.prnewswire.com/mnr/centraldupage/23271
Central DuPage Hospital
CONTACT: Anne Waliczek, anne_waliczek@cdh.org , or Mindy Kolof,mindy_kolof@cdh.org , both Public Relations of Central DuPage Hospital,+1-847-909-0318, or +1-847-317-0408; or Rick Schallhorn of CoAxia, Inc.,+1-763-315-1809
Web site: http://www.cdh.org/